AMN

AMN is a post-COVID hangover story. Revenue has fallen from a $5.24B 2022 peak to $2.73B in FY2025, and the company is now two years into GAAP losses (-$95.7M FY2025, -$147M FY2024) with a negative -2.0% operating margin and -14.9% ROE. The MD&A and risk factors frame the structural pressure honestly: hospitals are leaning on internal float pools, 'other healthcare staffing models,' and increasing AI adoption to cut their reliance on temp clinicians, while economic softness drives both lower admissions and pricing pressure. That is exactly what the gross margin (28.3%, gross profit down 15.8% YoY) is showing — this is a demand-and-price squeeze, not a one-off.

The offsetting case is that the bleeding is slowing and the cash engine still works. The revenue decline decelerated sharply — roughly -21% in 2024 to just -8.5% in 2025 — and the net loss narrowed ~35%. Despite GAAP red ink, the business threw off $269M of operating cash flow against only $35.6M of capex (~$233M free cash flow), helped by DSO improving from 70 to 55 to 47 days. Management used that cash to deleverage aggressively, redeeming the entire $500M 4.625% 2027 notes and cutting long-term debt 27.4%, while staying covenant-compliant with $404.8M of revolver availability. At $32.38 the stock trades at ~0.5x sales and a high-teens FCF yield on its $1.25B cap — the market is pricing in continued decline.